182 related articles for article (PubMed ID: 36323303)
1. Refractory Headaches.
Begasse de Dhaem O; Rizzoli P
Semin Neurol; 2022 Aug; 42(4):512-522. PubMed ID: 36323303
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
[TBL] [Abstract][Full Text] [Related]
3. [Chronic and Refractory Migraine: How to Diagnose and Treat].
Parreira E; Luzeiro I; Pereira Monteiro JM
Acta Med Port; 2020 Nov; 33(11):753-760. PubMed ID: 33160424
[TBL] [Abstract][Full Text] [Related]
4. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Moskatel LS; Graber-Naidich A; He Z; Zhang N
Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
[TBL] [Abstract][Full Text] [Related]
5. Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
Kaltseis K; Hamann T; Gaul C; Broessner G
Headache; 2022 Nov; 62(10):1264-1271. PubMed ID: 36437611
[TBL] [Abstract][Full Text] [Related]
6. 2022 Taiwan Guidelines for Preventive Treatment of Migraine.
Wu JW; Yang CP;
Acta Neurol Taiwan; 2022 Sep; 31(3)():164-202. PubMed ID: 36089629
[TBL] [Abstract][Full Text] [Related]
7. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
8. New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study.
Carrión-Nessi FS; Ascanio LC; Pineda-Arapé AG; Omaña-Ávila ÓD; Mendoza-Millán DL; Romero SR; Almao-Rivero AB; Camejo-Ávila NA; Gebran-Chedid KJ; Rodriguez-Saavedra CM; Freitas-De Nobrega DC; Castañeda SA; Forero-Peña JL; Delgado-Noguera LA; Meneses-Ramírez LK; Cotuá JC; Rodriguez-Morales AJ; Forero-Peña DA; Paniz-Mondolfi AE
BMC Infect Dis; 2023 Dec; 23(1):877. PubMed ID: 38097988
[TBL] [Abstract][Full Text] [Related]
9. The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update.
Sun-Edelstein C; Rapoport AM; Rattanawong W; Srikiatkhachorn A
CNS Drugs; 2021 May; 35(5):545-565. PubMed ID: 34002347
[TBL] [Abstract][Full Text] [Related]
10. A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role.
Grazzi L; Montisano DA; Rizzoli P; Guastafierro E; Marcassoli A; Fornari A; Raggi A
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828401
[TBL] [Abstract][Full Text] [Related]
11. Circulating nociceptin and CGRP in medication-overuse headache.
Munksgaard SB; Ertsey C; Frandsen E; Bendtsen L; Tekes K; Jensen RH
Acta Neurol Scand; 2019 Mar; 139(3):269-275. PubMed ID: 30457160
[TBL] [Abstract][Full Text] [Related]
12. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
13. Chronic migraine: current concepts and ongoing treatments.
Negro A; Rocchietti-March M; Fiorillo M; Martelletti P
Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1401-20. PubMed ID: 22288302
[TBL] [Abstract][Full Text] [Related]
14. New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and Treatment.
Sadeghpour M; Abdolizadeh A; Yousefi P; Rastegar-Kashkouli A; Chitsaz A
Curr Pain Headache Rep; 2023 Oct; 27(10):551-559. PubMed ID: 37632682
[TBL] [Abstract][Full Text] [Related]
15. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
Pensato U; Baraldi C; Favoni V; Cainazzo MM; Torelli P; Querzani P; Pascazio A; Mascarella D; Matteo E; Quintana S; Asioli GM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
[TBL] [Abstract][Full Text] [Related]
16. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
Negro A; Curto M; Lionetto L; Martelletti P
J Headache Pain; 2015; 17():1. PubMed ID: 26792662
[TBL] [Abstract][Full Text] [Related]
17. New daily persistent headache after SARS-CoV-2 infection: a report of two cases.
Dono F; Consoli S; Evangelista G; D'Apolito M; Russo M; Carrarini C; Calisi D; De Rosa M; Di Pietro M; De Angelis MV; Travaglini D; Sensi SL; Onofrj M; Bonanni L
Neurol Sci; 2021 Oct; 42(10):3965-3968. PubMed ID: 34264414
[TBL] [Abstract][Full Text] [Related]
18. The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine.
Martelletti P
J Headache Pain; 2018 Jan; 19(1):2. PubMed ID: 29322261
[TBL] [Abstract][Full Text] [Related]
19. Therapies targeting CGRP signaling for medication overuse headache.
Koumprentziotis IA; Mitsikostas DD
Curr Opin Neurol; 2022 Jun; 35(3):353-359. PubMed ID: 35674079
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
